Results 71 to 80 of about 3,349,315 (392)
The intracellular domain of TLR2 is capable of high‐affinity Zn binding: possible outcomes for the receptor activation
FEBS Letters, EarlyView.Toll‐like receptors (TLRs) are important in the innate immune system. This study explores the zinc‐binding ability of the TLR2 TIR domain (TLR2TIR). We found that TLR2TIR binds zinc with nanomolar affinity through its cysteine residues. Two of them, C673 and C713, are vital for receptor activation, indicating that zinc may play a role in initiating ...Vladislav A. Lushpa, Cong Lin, Irina A. Talyzina, Marina V. Goncharuk, Eduard V. Bocharov, Alexander S. Arseniev, Xiaohui Wang, Sergey A. Goncharuk, Konstantin S. Mineev +8 morewiley +1 more sourcePredicting Antibody Developability Profiles Through Early Stage Discovery Screening
mAbs, 2020 Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term ‘developability’ encompasses the feasibility of molecules to successfully progress from discovery to development via ...Marc Bailly, Carl Mieczkowski, Veronica Juan, Essam Metwally, Daniela Tomazela, Jeanne Baker, Makiko Uchida, Ester Kofman, Fahimeh Raoufi, Soha Motlagh, Yao Yu, Jihea Park, Smita Raghava, John Welsh, Michael Rauscher, Gopalan Raghunathan, Mark Hsieh, Yi-Ling Chen, Hang Thu Nguyen, Nhung Nguyen, Dan Cipriano, Laurence Fayadat-Dilman +21 moredoaj +1 more sourceLong-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab [PDF]
, 2020 Switching of biologic agents in treatment of plaque psoriasis is a common strategy. Only a few studies are available on switching between IL17A-blockers.Amschler, K, Gerdes, S, Mohr, J, Mössner, R, Phillip, S, Poortinga, S, Wilsmann-Theis, D +6 morecore +1 more sourceThe power of microRNA regulation—insights into immunity and metabolism
FEBS Letters, EarlyView.MicroRNAs are emerging as crucial regulators at the intersection of metabolism and immunity. This review examines how miRNAs coordinate glucose and lipid metabolism while simultaneously modulating T‐cell development and immune responses. Moreover, it highlights how cutting‐edge artificial intelligence applications can identify miRNA biomarkers ...Stefania Oliveto, Nicola Manfrini, Stefano Biffo +2 morewiley +1 more sourceTargeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors
BMC CancerBackground High levels of LLT1 expression have been found in several cancers, where it interacts with CD161 on NK cells to facilitate tumor immune escape.Tirtha Mandal, Soorya Gnanasegaran, Golding Rodrigues, Shalini Kashipathi, Anurag Tiwari, Ashvini Kumar Dubey, Sanghamitra Bhattacharjee, Yogendra Manjunath, Subith Krishna, M. S. Madhusudhan, Maloy Ghosh +10 moredoaj +1 more sourceDevelopability considerations for bispecific and multispecific antibodies
mAbsBispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of Alaa Amash, Gesa Volkers, Patrick Farber, Daniel Griffin, K. Shawn Davison, Allison Goodman, Raffi Tonikian, Aaron Yamniuk, Bryan Barnhart, Tim Jacobs +9 moredoaj +1 more sourceDiscovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants
Scientific Reports, 2023 Coronaviruses have been the causative agent of three epidemics and pandemics in the past two decades, including the ongoing COVID-19 pandemic. A broadly-neutralizing coronavirus therapeutic is desirable not only to prevent and treat COVID-19, but also to Scott A. Hollingsworth, Cameron L. Noland, Karin Vroom, Anasuya Saha, Miranda Sam, Qinshan Gao, Haihong Zhou, David U. Grandy, Sujata Singh, Zhiyun Wen, Christopher Warren, Xiaohong Shirley Ma, Daniel Malashock, Jennifer Galli, Gwenny Go, Michael Eddins, Todd Mayhood, Karthik Sathiyamoorthy, Arthur Fridman, Fahimeh Raoufi, Yacob Gomez-Llorente, Andrea Patridge, Yinyan Tang, Shi-Juan Chen, Marc Bailly, Chengjie Ji, Laura J. Kingsley, Alan C. Cheng, Bernhard H. Geierstanger, Daniel M. Gorman, Lan Zhang, Kalyan Pande +31 moredoaj +1 more sourceTildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. [PDF]
, 2019 Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of Lee, Erica B, Liao, Wilson, Pithadia, Deeti J, Reynolds, Kelly A, Wu, Jashin J +4 morecore Current trends in drug metabolism and pharmacokinetics. [PDF]
, 2019 Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication.Abduljalil, Aghazadeh-Habashi, Aigrain, Aitman, Al Za'abi, Alegre, Alnaqeeb, Aspromonte, Babiskin, Baert, Bakke, Barnett, Bhattacharyya, Cang, Cannady, Cao, Cao, Capecchi, Chen, Chen, Chen, Chen, Chen, Chen, Chen, Cheng, Cheng, Crawford, Currie, De Lange, Dean, Deng, Di Paolo, Dietrich, Diliberto, Dluzen, Dowling, Dragin, Dreisbach, Duan, Edeogu, Edginton, El-Arabey, El-Kadi, EMA, Eum, Falany, Fang, FDA, Feng, Feng, Feng, Ferri, Fleming, Foti, Fox, Freedman, Frye, Fukami, Gaj, Gan, Gao, Gao, Gao, Gao, Gao, Ge, Genovese, Gingell, Gingell, Gong, Graham, Gufford, Guo, Guo, Guo, Guévin, Han, Harrison, Hartz, Hasegawa, He, He, He, He, He, Ho, Ho, Hou, Hsu, Hsueh, Hu, Hu, Hu, Huo, Hwang, Ito, Jacob, Jeong, Jeong, Jia, Jian, Jiang, Jiang, Jiang, Jiang, Jilek, Jilek, Johnson, Jorga, Jung, Kaivosaari, Kalthoff, Kaminsky, Kannan, Karibe, Kesisoglou, Kim, Kim, Knights, Kong, Kota, Kumar, Kurokawa, Lai, Lan, Lanchote, Lee, Lehouritis, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Liang, Lin, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Lopes-Rodrigues, Lu, Lu, Lu, Löfgren, Mano, Marchitti, Margolskee, Martin, Matsson, Mattick, Mazerska, Mei, Mencia, Meng, Min, Mitra, Miyajima, Müller, Nair, Nakano, Nakano, Nakano, Nebert, Nguyen, Niederalt, Nieto Montesinos, Niu, Notenboom, Nozaki, Ohtsuki, Ono, Oostendorp, Pan, Pan, Papageorgiou, Papageorgiou, Park, Pea, Pedersen, Pelkonen, Pellegrino, Pettersson Bergstrand, Qi, Qin, Qiu, Qiu, Raaska, Rives, Riviere, Roberts, Robey, Rocha, Rose, Routy, Rowland, Ruwali, Saini, Satoh, Savage, Scheer, Scheer, Schlender, Schmitt, Schneider, Seitz, Showande, Shu, Shu, Shu, Shugarts, Siu, Song, Staudinger, Strong, Suarez-Sharp, Suh, Suiko, Sukkummee, Sun, Sun, Sutliff, Takeda, Tan, Tan, Tao, Tatsumi, Teorell, Tsai, Tsang, Tsuchiya, Tsume, Tu, Ulldemolins, van Waterschoot, von Richter, Vugmeyster, Vuppugalla, Wagner, Wagner, Wagner, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wassenaar, Watanabe, Wei, Wijayakumara, Wilkinson, Wong, Wu, Xia, Xie, Xie, Xu, Xu, Xu, Xu, Xu, Xue, Yamagata, Yamaguchi, Yan, Yang, Yang, Yang, Ye, Yellepeddi, Yi, Yi, Yigitaslan, Yim, Yin, Yoshida, Yoshida, Yoshimi, Yu, Yu, Yu, Yu, Yu, Yu, Yu, Zakeri-Milani, Zanger, Zeng, Zeng, Zhai, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhao, Zhao, Zhao, Zhao, Zhou, Zhou, Zhou, Zhou, Zhou, Zhu, Zhu, Zhu, Zhuang, Zimmermann +332 morecore +1 more source
